On Friday, Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX), gained 0.42% to $47.31.
Neurocrine Biosciences, declared that it has suspended two planned clinical studies of the Company’s CRF antagonist NBI-77860.
“Out of an abundance of caution, we halted the implementation of these studies and notified the FDA of certain preclinical findings that we had not observed in previous animal studies,” said Chris O’Brien, M.D., Chief Medical Officer at Neurocrine. “We intend to work closely with the FDA to elucidate these findings and determine the next steps for NBI-77860 in congenital adrenal hyperplasia.”
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company’s products in clinical development stage comprise elagolix, which is in Phase III study for endometriosis; elagolix that is in Phase IIb study for uterine fibroids; Corticotropin-Releasing Factor Receptor1 Antagonist, which is in Phase I/II study for congenital adrenal hyperplasia and stress-related disorders; and Vesicular Monoamine Transporter 2 Inhibitor (VMAT2) that is in Phase III study for movement disorders, in addition to Phase I study for tourette syndrome.
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), inclined 0.32% to $128.04, during its last trading session.
Vertex Pharmaceuticals Incorporated, declared that Sangeeta N. Bhatia, M.D., Ph.D., joined its board of directors as an independent director. Dr. Bhatia was elected to serve a three-year term ending in 2018.
“Dr. Bhatia is a leading physician scientist and medical researcher who brings a wealth of expertise to our board,” said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. “Her extensive experience in the field of biomedical engineering and in-depth understanding on the use of advanced technologies in medical research will provide valuable insights to our board and our company as we advance key research and development programs.”
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets.
At the end of Friday’s trade, Shares of Olin Corporation (NYSE:OLN), lost -1.20% to $27.91.
The Dow Chemical Company and Olin Corporation, declared the achievement of a regulatory milestone in the projected transaction involving a noteworthy portion of Dow’s chlorine value chain and Olin Corporation, with the expiration of the required waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976.
“This important milestone marks progress toward the close of a seminal transaction maximizing return for both Dow and Olin shareholders and the advancement of Dow’s targeted market participation and portfolio transformation strategies,” said Andrew N. Liveris, Dow’s chairman and chief executive officer.
Olin Corporation manufactures and sells chlor alkali products in the United States and internationally. The company operates through three segments: Chlor Alkali Products, Chemical Distribution, and Winchester.
Finally, Ingersoll-Rand PLC (NYSE:IR), ended its last trade with -0.63% loss, and close at $68.99.
Ingersoll-Rand PLC, declared advanced diagnostic features for heating, ventilation and air conditioning (HVAC) systems to give homeowners added peace of mind their system is performing optimally. When a homeowner opts in to Nexia Diagnostics, they allow remote HVAC system monitoring by their preferred HVAC dealer, which can assist prevent minor issues from turning into major repairs.
The diagnostic features are free for homeowners and their HVAC dealers. Accessible with Trane and American Standard Wi-Fi-enabled thermostats and a free Nexia account, the diagnostic features extend the value of the Nexia Home Intelligence system by providing HVAC technicians real-time and historical performance data on one of the home’s most expensive and complicated pieces of equipment.
Ingersoll-Rand plc, together with its auxiliaries, designs, manufactures, sells, and services a portfolio of industrial and commercial products. It operates through Climate and Industrial segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
